|
US6303121B1
(en)
|
1992-07-30 |
2001-10-16 |
Advanced Research And Technology |
Method of using human receptor protein 4-1BB
|
|
US6355476B1
(en)
|
1988-11-07 |
2002-03-12 |
Advanced Research And Technologyinc |
Nucleic acid encoding MIP-1α Lymphokine
|
|
US6362325B1
(en)
|
1988-11-07 |
2002-03-26 |
Advanced Research And Technology Institute, Inc. |
Murine 4-1BB gene
|
|
EP1400536A1
(en)
|
1991-06-14 |
2004-03-24 |
Genentech Inc. |
Method for making humanized antibodies
|
|
US5851795A
(en)
|
1991-06-27 |
1998-12-22 |
Bristol-Myers Squibb Company |
Soluble CTLA4 molecules and uses thereof
|
|
US5821332A
(en)
|
1993-11-03 |
1998-10-13 |
The Board Of Trustees Of The Leland Stanford Junior University |
Receptor on the surface of activated CD4+ T-cells: ACT-4
|
|
US6051227A
(en)
|
1995-07-25 |
2000-04-18 |
The Regents Of The University Of California, Office Of Technology Transfer |
Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
|
|
RU2192281C2
(ru)
|
1996-10-11 |
2002-11-10 |
Бристол-Маерс Сквибб Компани |
Способы и композиции для иммуномодуляции
|
|
US7112655B1
(en)
|
1997-02-27 |
2006-09-26 |
Japan Tobacco, Inc. |
JTT-1 protein and methods of inhibiting lymphocyte activation
|
|
JP3521382B2
(ja)
|
1997-02-27 |
2004-04-19 |
日本たばこ産業株式会社 |
細胞間接着及びシグナル伝達を媒介する細胞表面分子
|
|
DE19821060A1
(de)
|
1997-09-23 |
1999-04-15 |
Bundesrepublik Deutschland Let |
Ko-stimulierendes Polypeptid von T-Zellen, monoklonale Antikörper sowie die Herstellung und deren Verwendung
|
|
CA2305350C
(en)
|
1997-09-23 |
2015-04-07 |
Bundesrepublik Deutschland Letztvertreten Durch Den Direktor Des Robert-Koch-Instituts |
Costimulating polypeptide of t cells, monoclonal antibodies, and the preparation and use thereof
|
|
AP1261A
(en)
|
1998-02-24 |
2004-03-19 |
Sisters Of Providence In Oregon |
Composition containing an OX-40 receptor binding agent or a nucleic acid encoding the same and methods for enhancing antigen-specific immune response.
|
|
US6682736B1
(en)
|
1998-12-23 |
2004-01-27 |
Abgenix, Inc. |
Human monoclonal antibodies to CTLA-4
|
|
CZ302706B6
(cs)
|
1998-12-23 |
2011-09-14 |
Pfizer Inc. |
Lidská monoklonální protilátka, farmaceutická kompozice tuto protilátku obsahující, bunecná linie produkující tuto protilátku, izolovaná molekula kódující težký nebo lehký retezec uvedené protilátky, hostitelská bunka obsahující tuto izolovanou molek
|
|
BR0012196A
(pt)
|
1999-06-25 |
2002-03-19 |
Genentech Inc |
Método de tratamento de um tumor em mamìferos através do uso de conjugados de maitansinóide e anticorpo receptor anti-erbb e artigo industrializado
|
|
PL354286A1
(en)
|
1999-08-23 |
2003-12-29 |
Dana-Farber Cancer Institutedana-Farber Cancer Institute |
Pd-1, a receptor for b7-4, and uses therefor
|
|
EP1212422B1
(en)
|
1999-08-24 |
2007-02-21 |
Medarex, Inc. |
Human ctla-4 antibodies and their uses
|
|
JP2003520828A
(ja)
|
2000-01-27 |
2003-07-08 |
ジェネティクス インスティテュート，エルエルシー |
Ｃｔｌａ４（ｃｄ１５２）に対する抗体、これを含む結合体、およびその使用
|
|
DE60317677T2
(de)
|
2002-06-13 |
2008-10-30 |
Crucell Holland B.V. |
Ox40 (=cd134) rezeptor agonisten und therapeutische verwendung
|
|
CN1703233A
(zh)
|
2002-07-12 |
2005-11-30 |
米德列斯公司 |
防止蛋白氧化降解的方法和组合物
|
|
JP2006500921A
(ja)
|
2002-07-30 |
2006-01-12 |
ブリストル−マイヤーズ スクイブ カンパニー |
ヒト４−１ｂｂに対するヒト化抗体
|
|
CN101899114A
(zh)
|
2002-12-23 |
2010-12-01 |
惠氏公司 |
抗pd-1抗体及其用途
|
|
US20060104968A1
(en)
|
2003-03-05 |
2006-05-18 |
Halozyme, Inc. |
Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
|
|
NZ542873A
(en)
|
2003-03-05 |
2008-07-31 |
Halozyme Inc |
Soluble, neutral-active hyaluronidase activity glycoprotein (sHASEGP) that is produced with high yield in a mammalian expression system by introducing nucleic acids that lack a narrow region encoding amino acids in the carboxy terminus of the human PH20 cDNA
|
|
HRP20120845T1
(hr)
|
2003-07-02 |
2012-11-30 |
Innate Pharma |
Protutijela za pan-kir2dl nk-receptor i njihova uporaba u dijagnostici i lijeäśenju
|
|
HRP20170342T1
(hr)
|
2003-07-24 |
2017-05-19 |
Innate Pharma S.A. |
Metode i sastavi za povećanje učinkovitosti terapijskih protutijela koristeći tvari koje potenciraju nk stanice
|
|
US7288638B2
(en)
|
2003-10-10 |
2007-10-30 |
Bristol-Myers Squibb Company |
Fully human antibodies against human 4-1BB
|
|
WO2006003179A2
(en)
|
2004-07-01 |
2006-01-12 |
Novo Nordisk A/S |
Antibodies binding to receptors kir2dl1, -2, 3 but not kir2ds4 and their therapeutic use
|
|
PT1831258E
(pt)
|
2004-12-28 |
2016-01-07 |
Univ Genova |
Anticorpos monoclonais contra nkg2a
|
|
CN101103043A
(zh)
|
2005-01-06 |
2008-01-09 |
诺和诺德公司 |
Kir结合剂和使用其的方法
|
|
US20090196850A1
(en)
|
2005-01-06 |
2009-08-06 |
Novo Nordisk A/S |
Anti-Kir Combination Treatments and Methods
|
|
PT2343320T
(pt)
|
2005-03-25 |
2018-01-23 |
Gitr Inc |
Anticorpos anti-gitr e as suas utilizações
|
|
DK2439273T3
(da)
|
2005-05-09 |
2019-06-03 |
Ono Pharmaceutical Co |
Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika
|
|
HUE025208T2
(en)
|
2005-06-16 |
2016-03-29 |
Nektar Therapeutics |
Conjugates with degradable binding and polymer reagents useful in the preparation of such conjugates
|
|
PT1907424E
(pt)
|
2005-07-01 |
2015-10-09 |
Squibb & Sons Llc |
Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1)
|
|
CN101300272B
(zh)
|
2005-10-14 |
2013-09-18 |
依奈特制药公司 |
用于治疗增生性病症的组合物和方法
|
|
WO2007113648A2
(en)
|
2006-04-05 |
2007-10-11 |
Pfizer Products Inc. |
Ctla4 antibody combination therapy
|
|
MX2008015830A
(es)
|
2006-06-30 |
2009-01-09 |
Novo Nordisk As |
Anticuerpos anti-nkg2a y usos de los mismos.
|
|
CN105037549B
(zh)
|
2007-01-11 |
2018-09-28 |
诺和诺德公司 |
抗-kir抗体、制剂及其应用
|
|
AU2008247382B2
(en)
|
2007-05-07 |
2014-06-05 |
Medimmune, Llc |
Anti-ICOS antibodies and their use in treatment of oncology, transplantation and autoimmune disease
|
|
JP2008278814A
(ja)
|
2007-05-11 |
2008-11-20 |
Igaku Seibutsugaku Kenkyusho:Kk |
アゴニスティック抗ヒトｇｉｔｒ抗体による免疫制御の解除とその応用
|
|
BR122017025062B8
(pt)
|
2007-06-18 |
2021-07-27 |
Merck Sharp & Dohme |
anticorpo monoclonal ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotídeo e composição compreendendo o referido anticorpo ou fragmento
|
|
US8591886B2
(en)
|
2007-07-12 |
2013-11-26 |
Gitr, Inc. |
Combination therapies employing GITR binding molecules
|
|
ES2526355T3
(es)
|
2007-10-01 |
2015-01-09 |
Bristol-Myers Squibb Company |
Anticuerpos humanos que se adhieren a mesotelina, y usos de los mismos
|
|
EP2044949A1
(en)
|
2007-10-05 |
2009-04-08 |
Immutep |
Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response
|
|
CL2008003526A1
(es)
|
2007-11-30 |
2010-01-11 |
Medarex Inc |
Conjugado de anticuerpo-molécula asociada que comprende un anticuerpo monoclonal humano anti b7-h4/08e/b7x/b7s1/bl-cam/b3/leu-14/lyb-8 humana; composición que lo comprende; método in vitro de inhibición de célula tumoral que expresa b7-h4/08e/b7x/b7s1/bl-cam/b3/leu-14/lyb-8; y uso para tratar cancer.
|
|
KR20100110864A
(ko)
|
2008-01-24 |
2010-10-13 |
노보 노르디스크 에이/에스 |
인간화된 항-인간 ｎｋｇ2ａ 모노클로날 항체
|
|
EP2262837A4
(en)
|
2008-03-12 |
2011-04-06 |
Merck Sharp & Dohme |
PD-1 BINDING PROTEINS
|
|
KR20130116386A
(ko)
|
2008-04-14 |
2013-10-23 |
할로자임, 아이엔씨 |
히알루로난 관련 질환 및 상태 치료용 변형된 히알루로니다제 및 그 용도
|
|
AR072999A1
(es)
|
2008-08-11 |
2010-10-06 |
Medarex Inc |
Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
|
|
EP2367553B1
(en)
|
2008-12-05 |
2017-05-03 |
Novo Nordisk A/S |
Combination therapy to enhance nk cell mediated cytotoxicity
|
|
EA022752B1
(ru)
|
2008-12-09 |
2016-02-29 |
Галозим, Инк. |
Длинные растворимые полипептиды рн20 и их использование
|
|
EP3255060A1
(en)
|
2008-12-09 |
2017-12-13 |
F. Hoffmann-La Roche AG |
Anti-pd-l1 antibodies and their use to enhance t-cell function
|
|
US20110007023A1
(en)
|
2009-07-09 |
2011-01-13 |
Sony Ericsson Mobile Communications Ab |
Display device, touch screen device comprising the display device, mobile device and method for sensing a force on a display device
|
|
AU2013202020B2
(en)
|
2009-07-31 |
2014-11-27 |
F. Hoffmann-La Roche Ag |
Subcutaneous anti-HER2 antibody formulation
|
|
KR101790802B1
(ko)
|
2009-09-03 |
2017-10-27 |
머크 샤프 앤드 돔 코포레이션 |
항-ｇｉｔｒ 항체
|
|
AR078161A1
(es)
|
2009-09-11 |
2011-10-19 |
Hoffmann La Roche |
Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
|
|
EP2482849B1
(en)
|
2009-09-30 |
2018-06-06 |
Memorial Sloan-Kettering Cancer Center |
Combination immunotherapy for the treatment of cancer
|
|
PL2504364T3
(pl)
|
2009-11-24 |
2017-12-29 |
Medimmune Limited |
Ukierunkowane środki wiążące przeciwko B7-H1
|
|
EA201690310A1
(ru)
|
2010-04-13 |
2016-12-30 |
Селлдекс Терапьютикс Инк. |
Антитела, связывающие cd27 человека, и их применение
|
|
AU2011262758B8
(en)
|
2010-06-11 |
2014-09-04 |
Kyowa Kirin Co., Ltd. |
Anti-tim-3 antibody
|
|
WO2011159877A2
(en)
|
2010-06-18 |
2011-12-22 |
The Brigham And Women's Hospital, Inc. |
Bi-specific antibodies against tim-3 and pd-1 for immunotherapy in chronic immune conditions
|
|
CA2809089C
(en)
|
2010-08-23 |
2018-12-18 |
Board Of Regents, The University Of Texas System |
Anti-ox40 antibodies and methods of using the same
|
|
WO2012065086A1
(en)
|
2010-11-12 |
2012-05-18 |
Nektar Therapeutics |
Conjugates of an il-2 moiety and a polymer
|
|
EP2643350A4
(en)
|
2010-11-22 |
2015-01-07 |
Innate Pharma Sa |
TREATMENTS WITH NK CELL MODULATION AND METHOD FOR THE TREATMENT OF HEMATOLOGICAL MALIGNOMES
|
|
CA2828940C
(en)
|
2011-03-10 |
2024-04-16 |
Provectus Pharmaceuticals, Inc. |
Combination of local and systemic immunomodulative therapies for enhanced treatment of cancer
|
|
EP3147297B1
(en)
|
2011-03-31 |
2018-12-12 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Antibodies directed against icos and uses thereof
|
|
JP6072771B2
(ja)
|
2011-04-20 |
2017-02-01 |
メディミューン，エルエルシー |
Ｂ７−ｈ１およびｐｄ−１に結合する抗体およびその他の分子
|
|
ES2765874T3
(es)
|
2011-05-25 |
2020-06-11 |
Innate Pharma Sa |
Anticuerpos anti-KIR para el tratamiento de trastornos inflamatorios
|
|
US20130011378A1
(en)
|
2011-06-17 |
2013-01-10 |
Tzung-Horng Yang |
Stable formulations of a hyaluronan-degrading enzyme
|
|
NZ618331A
(en)
|
2011-06-17 |
2016-04-29 |
Halozyme Inc |
Stable formulations of a hyaluronan-degrading enzyme
|
|
CA2839512C
(en)
|
2011-06-17 |
2018-01-02 |
Halozyme, Inc. |
Continuous subcutaneous insulin infusion methods with a hyaluronan-degrading enzyme
|
|
WO2013006490A2
(en)
|
2011-07-01 |
2013-01-10 |
Cellerant Therapeutics, Inc. |
Antibodies that specifically bind to tim3
|
|
CA2845810C
(en)
|
2011-08-23 |
2017-03-28 |
Board Of Regents, The University Of Texas System |
Anti-ox40 antibodies and methods of using the same
|
|
WO2013039954A1
(en)
|
2011-09-14 |
2013-03-21 |
Sanofi |
Anti-gitr antibodies
|
|
GB201116092D0
(en)
|
2011-09-16 |
2011-11-02 |
Bioceros B V |
Antibodies and uses thereof
|
|
KR101764096B1
(ko)
|
2011-11-28 |
2017-08-02 |
메르크 파텐트 게엠베하 |
항-ｐｄ-ｌ1 항체 및 그의 용도
|
|
WO2013102144A2
(en)
|
2011-12-30 |
2013-07-04 |
Halozyme, Inc. |
Ph20 polypeptede variants, formulations and uses thereof
|
|
HK1203971A1
(en)
|
2012-05-15 |
2015-11-06 |
Bristol-Myers Squibb Company |
Cancer immunotherapy by disrupting pd-1/pd-l1 signaling
|
|
KR20220084444A
(ko)
|
2012-05-31 |
2022-06-21 |
소렌토 쎄라퓨틱스, 인코포레이티드 |
Pd-l1에 결합하는 항원 결합 단백질
|
|
KR101566539B1
(ko)
|
2012-06-08 |
2015-11-05 |
국립암센터 |
신규한 Ｔｈ2 세포 전환용 에피토프 및 이의 용도
|
|
UY34887A
(es)
|
2012-07-02 |
2013-12-31 |
Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware |
Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
|
|
PL2904011T3
(pl)
|
2012-10-02 |
2018-01-31 |
Bristol Myers Squibb Co |
Połączenie przeciwciał anty-kir i przeciwciał anty-pd-1 w leczeniu raka
|
|
US10344088B2
(en)
|
2013-03-15 |
2019-07-09 |
Glaxosmithkline Intellectual Property Development Limited |
Antigen binding proteins
|
|
SG10201708048XA
(en)
|
2013-03-18 |
2017-10-30 |
Biocerox Prod Bv |
Humanized anti-cd134 (ox40) antibodies and uses thereof
|
|
SMT202100065T1
(it)
|
2013-05-02 |
2021-03-15 |
Anaptysbio Inc |
Anticorpi diretti contro la proteina della morte programmata (pd-1)
|
|
WO2014194302A2
(en)
|
2013-05-31 |
2014-12-04 |
Sorrento Therapeutics, Inc. |
Antigen binding proteins that bind pd-1
|
|
CN104250302B
(zh)
|
2013-06-26 |
2017-11-14 |
上海君实生物医药科技股份有限公司 |
抗pd‑1抗体及其应用
|
|
TW201534726A
(zh)
|
2013-07-03 |
2015-09-16 |
Halozyme Inc |
熱穩定ｐｈ２０玻尿酸酶變異體及其用途
|
|
AR097306A1
(es)
|
2013-08-20 |
2016-03-02 |
Merck Sharp & Dohme |
Modulación de la inmunidad tumoral
|
|
TW201605896A
(zh)
|
2013-08-30 |
2016-02-16 |
安美基股份有限公司 |
Gitr抗原結合蛋白
|
|
CN112552401B
(zh)
|
2013-09-13 |
2023-08-25 |
广州百济神州生物制药有限公司 |
抗pd1抗体及其作为治疗剂与诊断剂的用途
|
|
JP6595458B2
(ja)
|
2013-09-20 |
2019-10-23 |
ブリストル−マイヤーズ スクイブ カンパニー |
腫瘍を処置するための抗ｌａｇ−３抗体と抗ｐｄ−１抗体との組合せ
|
|
SG10201804945WA
(en)
|
2013-12-12 |
2018-07-30 |
Shanghai hengrui pharmaceutical co ltd |
Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof
|
|
TWI681969B
(zh)
|
2014-01-23 |
2020-01-11 |
美商再生元醫藥公司 |
針對ｐｄ-１的人類抗體
|
|
PE20170255A1
(es)
|
2014-01-24 |
2017-03-22 |
Dana Farber Cancer Inst Inc |
Moleculas de anticuerpo que se unen a pd-1 y usos de las mismas
|
|
HUE045065T2
(hu)
|
2014-01-31 |
2019-12-30 |
Novartis Ag |
TIM-3 antitest molekulák és felhasználásaik
|
|
KR102410090B1
(ko)
|
2014-02-21 |
2022-06-16 |
넥타르 테라퓨틱스 (인디아) 프라이빗 리미티드 |
항-ｃｔｌａ－４ 항체 또는 항-ｐｄ－１ 항체와 조합한 ｉｌ－２ｒ베타-선택적 효현제
|
|
KR102442436B1
(ko)
|
2014-03-14 |
2022-09-15 |
노파르티스 아게 |
Lag-3에 대한 항체 분자 및 그의 용도
|
|
KR20160146747A
(ko)
|
2014-03-31 |
2016-12-21 |
제넨테크, 인크. |
항혈관신생제 및 ox40 결합 효능제를 포함하는 조합 요법
|
|
SG11201607969XA
(en)
|
2014-03-31 |
2016-10-28 |
Genentech Inc |
Anti-ox40 antibodies and methods of use
|
|
MX2016014434A
(es)
|
2014-05-13 |
2017-02-23 |
Chugai Pharmaceutical Co Ltd |
Molecula de union a antigeno redirigida a celulas t para celulas que tienen funcion de inmunosupresion.
|
|
SI3148579T1
(sl)
|
2014-05-28 |
2021-07-30 |
Agenus Inc. |
Proti GITR antitelesa in postopki z njihovo uporabo
|
|
TWI693232B
(zh)
|
2014-06-26 |
2020-05-11 |
美商宏觀基因股份有限公司 |
與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法
|
|
JO3663B1
(ar)
|
2014-08-19 |
2020-08-27 |
Merck Sharp & Dohme |
الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
|
|
PT3186281T
(pt)
*
|
2014-08-28 |
2019-07-10 |
Halozyme Inc |
Terapia de combinação com uma enzima de degradação de hialuronano e um inibidor de pontos de verificação imunológica
|
|
RU2017105425A
(ru)
|
2014-08-28 |
2018-09-28 |
Академиш Зикенхёйс Лейден Х.О.Д.Н. Люмк |
Комбинации антитела против cd94/nkg2a и/или cd94/nkg2b и вакцины
|
|
AU2015316991B2
(en)
|
2014-09-16 |
2021-04-01 |
Innate Pharma |
Neutralization of inhibitory pathways in lymphocytes
|
|
SG10202007781TA
(en)
|
2014-09-16 |
2020-09-29 |
Innate Pharma |
Treatment Regimens Using Anti-NKG2A Antibodies
|
|
TW201619200A
(zh)
|
2014-10-10 |
2016-06-01 |
麥迪紐有限責任公司 |
人類化抗－ｏｘ４０抗體及其用途
|
|
KR20170075778A
(ko)
|
2014-10-27 |
2017-07-03 |
에이전시 포 사이언스, 테크놀로지 앤드 리서치 |
항-tim-3 항체
|
|
GB201419094D0
(en)
|
2014-10-27 |
2014-12-10 |
Agency Science Tech & Res |
Anti-TIM-3-antibodies
|
|
SI3215532T1
(sl)
|
2014-11-06 |
2020-02-28 |
F. Hoffmann-La Roche Ag |
Protitelesa proti TIM3 in postopki uporabe
|
|
DK3237446T3
(en)
|
2014-12-22 |
2021-07-26 |
Pd 1 Acquisition Group Llc |
Anti-PD-1-antistoffer
|
|
JP6180663B2
(ja)
|
2014-12-23 |
2017-08-16 |
ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ |
Ｔｉｇｉｔに対する抗体
|
|
WO2016111947A2
(en)
|
2015-01-05 |
2016-07-14 |
Jounce Therapeutics, Inc. |
Antibodies that inhibit tim-3:lilrb2 interactions and uses thereof
|
|
MA41414A
(fr)
|
2015-01-28 |
2017-12-05 |
Centre Nat Rech Scient |
Protéines de liaison agonistes d' icos
|
|
MA41463A
(fr)
|
2015-02-03 |
2017-12-12 |
Anaptysbio Inc |
Anticorps dirigés contre le gène d'activation 3 des lymphocytes (lag-3)
|
|
WO2016134371A2
(en)
|
2015-02-20 |
2016-08-25 |
Ohio State Innovation Foundation |
Bivalent antibody directed against nkg2d and tumor associated antigens
|
|
EP3265486A4
(en)
|
2015-03-06 |
2018-11-14 |
Sorrento Therapeutics, Inc. |
Antibody therapeutics that bind tim3
|
|
CN108112254B
(zh)
|
2015-03-13 |
2022-01-28 |
西托姆克斯治疗公司 |
抗-pdl1抗体、可活化的抗-pdl1抗体、及其使用方法
|
|
RS60614B1
(sr)
|
2015-03-23 |
2020-08-31 |
Jounce Therapeutics Inc |
Antitela za icos
|
|
FI3277321T3
(fi)
|
2015-04-01 |
2024-10-31 |
Anaptysbio Inc |
T-soluimmunoglobuliinia ja musiiniproteiini 3:a (tim-3) vastaan suunnattuja vasta-aineita
|
|
KR20250004095A
(ko)
|
2015-04-17 |
2025-01-07 |
브리스톨-마이어스 스큅 컴퍼니 |
항-pd-1 항체 및 또 다른 항체의 조합물을 포함하는 조성물
|
|
MA53355A
(fr)
|
2015-05-29 |
2022-03-16 |
Agenus Inc |
Anticorps anti-ctla-4 et leurs procédés d'utilisation
|
|
DK3303396T5
(da)
|
2015-05-29 |
2024-10-07 |
Bristol Myers Squibb Co |
Antistoffer mod ox40 og anvendelser deraf
|
|
TWI773646B
(zh)
|
2015-06-08 |
2022-08-11 |
美商宏觀基因股份有限公司 |
結合lag-3的分子和其使用方法
|
|
JP2018521019A
(ja)
|
2015-06-08 |
2018-08-02 |
ジェネンテック， インコーポレイテッド |
抗ｏｘ４０抗体を使用して癌を治療する方法
|
|
WO2016197367A1
(en)
|
2015-06-11 |
2016-12-15 |
Wuxi Biologics (Shanghai) Co. Ltd. |
Novel anti-pd-l1 antibodies
|
|
EP3307280B1
(en)
*
|
2015-06-11 |
2021-10-27 |
Rejoy |
Treatment of sexual dysfunction
|
|
CN114853891A
(zh)
|
2015-07-22 |
2022-08-05 |
索伦托药业有限公司 |
与lag3结合的抗体治疗剂
|
|
HRP20211058T8
(hr)
|
2015-07-29 |
2021-11-26 |
Novartis Ag |
Kombinirane terapije koje sadrže molekule antitijela protiv lag-3
|
|
HUE068868T2
(hu)
|
2015-07-30 |
2025-02-28 |
Macrogenics Inc |
PD-1-hez kötõdõ molekulák és alkalmazásukra szolgáló eljárások
|
|
WO2017020291A1
(en)
|
2015-08-06 |
2017-02-09 |
Wuxi Biologics (Shanghai) Co. Ltd. |
Novel anti-pd-l1 antibodies
|
|
CA2994631A1
(en)
|
2015-08-07 |
2017-02-16 |
Pieris Pharmaceuticals Gmbh |
Novel fusion polypeptide specific for lag-3 and pd-1
|
|
WO2017024465A1
(en)
|
2015-08-10 |
2017-02-16 |
Innovent Biologics (Suzhou) Co., Ltd. |
Pd-1 antibodies
|
|
WO2017024515A1
(en)
|
2015-08-11 |
2017-02-16 |
Wuxi Biologics (Cayman) Inc. |
Novel anti-pd-1 antibodies
|
|
EP4458417A3
(en)
|
2015-08-11 |
2025-02-19 |
Wuxi Biologics Ireland Limited |
Novel anti-pd-1 antibodies
|
|
EP3337826A1
(en)
|
2015-08-20 |
2018-06-27 |
Sutro Biopharma, Inc. |
Anti-tim-3 antibodies, compositions comprising anti-tim-3 antibodies and methods of making and using anti-tim-3 antibodies
|
|
AR105654A1
(es)
|
2015-08-24 |
2017-10-25 |
Lilly Co Eli |
Anticuerpos pd-l1 (ligando 1 de muerte celular programada)
|
|
AU2016317915B2
(en)
|
2015-09-01 |
2021-02-18 |
Agenus Inc. |
Anti-PD-1 antibodies and methods of use thereof
|
|
PE20181046A1
(es)
|
2015-09-25 |
2018-07-03 |
Genentech Inc |
Anticuerpos anti-tigit y metodos de uso
|
|
JP6734919B2
(ja)
|
2015-10-02 |
2020-08-05 |
エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ |
同時結合を測定するための細胞ベースのｆｒｅｔアッセイ法
|
|
WO2017055404A1
(en)
|
2015-10-02 |
2017-04-06 |
F. Hoffmann-La Roche Ag |
Bispecific antibodies specific for pd1 and tim3
|
|
TWI756187B
(zh)
|
2015-10-09 |
2022-03-01 |
美商再生元醫藥公司 |
抗ｌａｇ３抗體及其用途
|
|
WO2017063162A1
(zh)
|
2015-10-15 |
2017-04-20 |
苏州丁孚靶点生物技术有限公司 |
抗ox40抗体及其应用
|
|
PE20181326A1
(es)
|
2015-11-03 |
2018-08-20 |
Janssen Biotech Inc |
Anticuerpos que se unen especificamente a pd-1 y sus usos
|
|
US10781261B2
(en)
*
|
2015-11-03 |
2020-09-22 |
Janssen Biotech, Inc. |
Subcutaneous formulations of anti-CD38 antibodies and their uses
|
|
US20170121417A1
(en)
|
2015-11-03 |
2017-05-04 |
Janssen Biotech, Inc. |
Subcutaneous Formulations of Anti-CD38 Antibodies and Their Uses
|
|
WO2017086367A1
(ja)
|
2015-11-18 |
2017-05-26 |
中外製薬株式会社 |
免疫抑制機能を有する細胞に対するｔ細胞リダイレクト抗原結合分子を用いた併用療法
|
|
WO2017086419A1
(ja)
|
2015-11-18 |
2017-05-26 |
中外製薬株式会社 |
液性免疫応答の増強方法
|
|
IL300122A
(en)
|
2015-11-18 |
2023-03-01 |
Merck Sharp ַ& Dohme Llc |
Substances that bind to PD1 and/or LAG3
|
|
US20190330336A1
(en)
|
2015-11-19 |
2019-10-31 |
Sutro Biopharma, Inc. |
Anti-lag3 antibodies, compositions comprising anti-lag3 antibodies and methods of making and using anti-lag3 antibodies
|
|
CN108883173B
(zh)
|
2015-12-02 |
2022-09-06 |
阿吉纳斯公司 |
抗体和其使用方法
|
|
MA43389A
(fr)
|
2015-12-02 |
2021-05-12 |
Agenus Inc |
Anticorps anti-ox40 et leurs procédés d'utilisation
|
|
AU2016364891A1
(en)
|
2015-12-03 |
2018-06-07 |
Agenus Inc. |
Anti-OX40 antibodies and methods of use thereof
|
|
IL260021B
(en)
|
2015-12-14 |
2022-09-01 |
Macrogenics Inc |
Bispecific molecules that are immunoreactive for pd1 and ctla4 and methods for using them
|
|
US11045547B2
(en)
|
2015-12-16 |
2021-06-29 |
Merck Sharp & Dohme Corp. |
Anti-LAG3 antibodies and antigen-binding fragments
|
|
US11814679B2
(en)
|
2016-01-11 |
2023-11-14 |
Eli Lilly And Company |
Interleukin-10 production of antigen-specific CD8+ T cells and methods of use of same
|
|
WO2017132827A1
(en)
|
2016-02-02 |
2017-08-10 |
Innovent Biologics (Suzhou) Co., Ltd. |
Pd-1 antibodies
|
|
CN108029076B
(zh)
|
2016-02-02 |
2020-03-10 |
华为技术有限公司 |
确定发射功率的方法、用户设备和基站
|
|
WO2017134292A1
(en)
|
2016-02-04 |
2017-08-10 |
Glenmark Pharmaceuticals S.A. |
Anti-ox40 antagonistic antibodies for the treatment of atopic dermatitis
|
|
SG10201601719RA
(en)
|
2016-03-04 |
2017-10-30 |
Agency Science Tech & Res |
Anti-LAG-3 Antibodies
|
|
PH12018502112B1
(en)
|
2016-04-12 |
2024-03-27 |
Servier Lab |
Anti-tim-3 antibodies and compositions
|
|
RS61510B1
(sr)
|
2016-05-18 |
2021-03-31 |
Boehringer Ingelheim Int |
Anti pd-1 i anti-lag3 antitela za lečenje kancera
|
|
EP3464360B1
(en)
|
2016-05-27 |
2025-11-12 |
Agenus Inc. |
Anti-tim-3 antibodies and methods of use thereof
|
|
RU2769282C2
(ru)
|
2016-06-20 |
2022-03-30 |
Кимаб Лимитед |
Анти-PD-L1 и IL-2 цитокины
|
|
HRP20210602T1
(hr)
|
2016-06-20 |
2021-05-14 |
F-Star Delta Limited |
Vezujuće molekule koje vežu pd-l1 i lag-3
|
|
SG11201811184UA
(en)
|
2016-06-20 |
2019-01-30 |
F Star Beta Ltd |
Lag -3 binding members
|
|
US11155617B2
(en)
|
2016-06-23 |
2021-10-26 |
Jiangsu Hengrui Medicine Co., Ltd. |
LAG-3 antibody, antigen-binding fragment thereof, and pharmaceutical application thereof
|
|
US20190233533A1
(en)
*
|
2016-06-28 |
2019-08-01 |
Umc Utrecht Holding B.V. |
Treatment Of IgE-Mediated Diseases With Antibodies That Specifically Bind CD38
|
|
CN109757103B
(zh)
|
2016-07-14 |
2024-01-02 |
百时美施贵宝公司 |
针对tim3的抗体及其用途
|
|
JP7054144B2
(ja)
|
2016-08-15 |
2022-04-13 |
国立大学法人北海道大学 |
抗ｌａｇ－３抗体
|
|
JOP20190013A1
(ar)
|
2016-08-25 |
2019-01-31 |
Lilly Co Eli |
أجسام مضادة لـ (تي آي ام -3)
|
|
US11203637B2
(en)
|
2016-08-26 |
2021-12-21 |
Beigene, Ltd. |
Anti-Tim-3 antibodies and use thereof
|
|
JP7066696B2
(ja)
|
2016-10-11 |
2022-05-13 |
アジェナス インコーポレイテッド |
抗ｌａｇ－３抗体及びその使用方法
|
|
PH12019500668B1
(en)
|
2016-10-13 |
2023-12-06 |
Chia Tai Tianqing Pharmaceutical Group Co Ltd |
Anti-lag-3 antibodies and compositions
|
|
WO2018083087A2
(en)
|
2016-11-02 |
2018-05-11 |
Glaxosmithkline Intellectual Property (No.2) Limited |
Binding proteins
|
|
TW202508629A
(zh)
*
|
2017-01-17 |
2025-03-01 |
美商建南德克公司 |
皮下her2抗體調配物
|
|
EP4516809A3
(en)
|
2017-04-05 |
2025-09-03 |
F. Hoffmann-La Roche AG |
Bispecific antibodies specifically binding to pd1 and lag3
|
|
KR102294136B1
(ko)
|
2017-04-05 |
2021-08-26 |
에프. 호프만-라 로슈 아게 |
항-lag3 항체
|
|
SG11201909395TA
(en)
|
2017-04-27 |
2019-11-28 |
Tesaro Inc |
Antibody agents directed against lymphocyte activation gene-3 (lag-3) and uses thereof
|
|
JP7382232B2
(ja)
|
2017-05-02 |
2023-11-16 |
メルク・シャープ・アンド・ドーム・エルエルシー |
抗ｌａｇ３抗体の製剤および抗ｌａｇ３抗体と抗ｐｄ－１抗体との共製剤
|
|
KR102770786B1
(ko)
|
2017-05-02 |
2025-02-20 |
머크 샤프 앤드 돔 엘엘씨 |
항-tigit 항체 단독의, 및 프로그램화된 사멸 수용체 1 (pd-1) 항체와 조합된 항-tigit 항체의 안정한 제제 및 그의 사용 방법
|
|
JOP20190260A1
(ar)
|
2017-05-02 |
2019-10-31 |
Merck Sharp & Dohme |
صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
|
|
US11339218B2
(en)
|
2017-05-10 |
2022-05-24 |
Zhejiang Shimai Pharmaceutical Co., Ltd. |
Human monoclonal antibodies against LAG3 and uses thereof
|
|
WO2018217944A1
(en)
|
2017-05-24 |
2018-11-29 |
Sutro Biopharma, Inc. |
Pd-1/lag3 bi-specific antibodies, compositions thereof, and methods of making and using the same
|
|
CN110678200B
(zh)
|
2017-05-30 |
2024-05-17 |
百时美施贵宝公司 |
包含抗lag-3抗体或抗lag-3抗体和抗pd-1或抗pd-l1抗体的组合物
|
|
JP6896989B2
(ja)
|
2017-07-13 |
2021-06-30 |
ナンジン リーズ バイオラブズ カンパニー リミテッド |
抗体結合ｌａｇ−３及びその使用
|
|
JP2020527572A
(ja)
|
2017-07-20 |
2020-09-10 |
ノバルティス アーゲー |
抗ｌａｇ−３抗体の投薬量レジメンおよびその使用
|
|
EP3768715A1
(en)
|
2018-03-23 |
2021-01-27 |
Bristol-Myers Squibb Company |
Antibodies against mica and/or micb and uses thereof
|
|
MX2020009824A
(es)
|
2018-07-25 |
2021-01-15 |
Alteogen Inc |
Nuevas variantes de hialuronidasa y composicion farmaceutica que comprende la misma.
|
|
US20210388070A1
(en)
|
2018-10-30 |
2021-12-16 |
Alexion Pharmaceuticals, Inc. |
Co-administration of a hyaluronidase and anti-c5 antibody for treatment of complement-associated conditions
|
|
EP3876978A4
(en)
*
|
2018-11-07 |
2022-09-28 |
Merck Sharp & Dohme Corp. |
STABLE FORMULATIONS OF PROGRAMMED DEATH RECEPTOR 1 (PD-1) ANTIBODIES AND METHODS OF USE THEREOF
|
|
CN113316590B
(zh)
|
2018-11-16 |
2025-02-28 |
百时美施贵宝公司 |
抗nkg2a抗体及其用途
|
|
KR102650991B1
(ko)
*
|
2019-03-25 |
2024-03-27 |
(주)알테오젠 |
인간 히알루로니다제 ph20의 변이체와 약물을 포함하는 피하투여용 약학 조성물
|
|
WO2020194245A1
(en)
*
|
2019-03-28 |
2020-10-01 |
Janssen Biotech, Inc. |
Clinically proven subcutaneous pharmaceutical compositions comprising anti-cd38 antibodies and their uses in combination with bortezomib, melphalan and prednisone
|
|
CN120699939A
(zh)
|
2020-01-23 |
2025-09-26 |
阿特根公司 |
具有改善的稳定性的新玻尿酸酶变体及含有其的药物组合物
|
|
US20220233693A1
(en)
|
2020-12-28 |
2022-07-28 |
Bristol-Myers Squibb Company |
Antibody Compositions and Methods of Use Thereof
|